Pfizer IncPfizer offers a high forward dividend yield of 7.1% and is expected to benefit from products like Padcev and Abrysvo, along with a promising pipeline.
Pfizer, Novo Nordisk, and Sanofi are highlighted as high-yield dividend stocks to buy and hold despite recent challenges. Pfizer offers a forward dividend yield of 7.1% and is expected to benefit from products like Padcev and Abrysvo, along with a promising pipeline in oncology and weight loss. Novo Nordisk, with a 3.6% forward yield, remains a leader in diabetes and weight loss markets and is advancing candidates such as zenagamtide and CagriSema, while also diversifying into rare blood diseases. Sanofi provides a 5.6% forward yield, driven by the strong performance of Dupixent and pipeline prospects like frexalimab, which could generate over $1 billion in peak annual sales.
Pfizer IncPfizer offers a high forward dividend yield of 7.1% and is expected to benefit from products like Padcev and Abrysvo, along with a promising pipeline.
Regeneron Pharmaceuticals Inc
Novo Nordisk A/SNovo Nordisk remains a leader in diabetes and weight loss markets with advancing candidates and diversification into rare blood diseases.
Sanofi SASanofi is driven by strong Dupixent performance and pipeline prospects like frexalimab with potential peak sales over $1 billion.